Duloxetine
Product Images NDC 50090-2844

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-2844). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

A line graph showing the proportion of patients with relapse over time (days) from randomization for two groups: placebo and duloxetine. The x-axis represents time in days, and the y-axis represents the proportion of patients with relapse, comparing the treatment effects.*

FDA Label Image

Fig2 (Duloxetine Fig2)

A Kaplan-Meier curve displaying the proportion of patients with relapse over time in days from randomization. The graph compares two treatments: placebo (dashed line) and Duloxetine (solid line), showing relapse rates over approximately 275 days.*

FDA Label Image

Figure 3: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-1)

Line graph showing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine and placebo groups. The graph includes data curves for Duloxetine 60 mg BID, 60 mg QD, 20 mg QD, and placebo, illustrating comparative patient response rates across varying thresholds of pain improvement.*

FDA Label Image

Figure 4: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-2)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, illustrating higher patient improvement percentages for Duloxetine dosages compared to placebo across increasing pain improvement thresholds.*

FDA Label Image

Figure 7: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-1 (Duloxetine Fig5)

A line graph depicting the percentage of patients improved against percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The graph shows higher patient improvement percentages for both Duloxetine regimens compared to placebo across the pain improvement spectrum.*

FDA Label Image

Figure 8: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-3 (Duloxetine Fig6)

A line graph showing the percent of patients improved as a function of percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and a placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percent of patients improved (0 to 100%). The Duloxetine groups show higher percentages of patient improvement compared to placebo across the range.*

FDA Label Image

Figure 9: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Oa-1 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo groups. The graph shows two lines with markers indicating patient response across ranges of pain improvement percentages.*

FDA Label Image

Duloxetine Fig8

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline with Duloxetine 60 mg once daily versus placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine data are represented with solid diamonds, and placebo with crosses, showing higher patient improvement percentages for Duloxetine across various pain improvement levels.*

FDA Label Image

Duloxetine Fig9

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60/120 mg once daily versus Placebo. The graph shows data points across improvement percentages from greater than 0 to 100%, illustrating a higher percentage of patient improvement with Duloxetine compared to Placebo.*

FDA Label Image

Structure (Duloxetine Str)

Chemical structure of duloxetine hydrochloride, depicting its molecular composition with a naphthyl group, thiophene ring, and an amine group as part of the active ingredient.*

FDA Label Image

Label Image (Lbl500902844)

Duloxetine 60 mg delayed-release unit dose capsules label from A-S Medication Solutions. The label includes NDC 50090-2844-0, lot number, storage instructions at 68 to 77 degrees Fahrenheit, and a QR code. It indicates quantity of 30 delayed-release unit dose capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.